Loading organizations...
§ Private Profile · Kuopio, Eastern Finland, Finland
Clinical-stage synthetic biology uses engineered bacteria for chronic wounds, cancers, inflammatory diseases.
Aurealis Therapeutics is a clinical-stage synthetic biology company based in Basel, Switzerland, and Kuopio, Finland, that develops genetically engineered bacteria to deliver multi-target cell and gene therapies directly to diseased tissues. The biotechnology firm utilizes live lactic acid bacteria as microscopic bioreactors to produce therapeutic proteins for the treatment of chronic wounds, inflammatory diseases, and oncology indications such as ovarian and melanoma cancers. The enterprise recently advanced its lead product candidate, AUP-16, into Phase 2 clinical trials for patients suffering from chronic diabetic foot ulcers following the publication of positive Phase 1 results. To support its clinical development and research operations, the company has raised over CHF 10 million in Series A funding from institutional backers including Swisscanto Private Equity, Finnvera, and Business Finland. Aurealis Therapeutics was founded in 2010 by Thomas Wirth and Juha Yrjänheikki.
Aurealis Therapeutics has raised $10.0M across 1 funding round.
Aurealis Therapeutics has raised $10.0M in total across 1 funding round.
Aurealis Therapeutics has raised $10.0M across 1 funding round. Most recently, it raised $10.0M Series A in April 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 4, 2023 | $10M Series A | Lynx Financial, Tesi | Huahai Pharmaceuticals | Announced |
Aurealis Therapeutics has raised $10.0M in total across 1 funding round.
Aurealis Therapeutics's investors include Lynx Financial, Tesi, Huahai Pharmaceuticals.